Group 1 - The company, JieTe Bio (688026.SH), announced its first share buyback on January 28, 2026, through the Shanghai Stock Exchange [1] - A total of 272,799 shares were repurchased, representing 0.19% of the company's total share capital [1] - The buyback was executed at a maximum price of 18.43 yuan per share and a minimum price of 18.05 yuan per share, with a total expenditure of 4.9714 million yuan (excluding transaction commissions) [1]

Core Viewpoint - He Yuan Bio is expected to report a net loss of between 143 million to 167 million yuan for the year 2025, indicating ongoing financial challenges despite product launches and revenue growth [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -191 million to -162 million yuan for 2025 [1] - The overall performance remains in a loss state during the reporting period due to various factors [1] Product Development - The product "Aofumin" (recombinant human albumin injection) has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the annual output of 10 tons of recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1] Research and Development - The company continues to maintain high levels of investment in research and development [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, with a net profit excluding non-recurring gains and losses estimated between -90.56 million and -74.09 million yuan, and operating revenue projected to be between 198.31 million and 242.38 million yuan [1] Group 1 - During the reporting period, the company's production and operational activities were normal, and it actively engaged in various marketing and market exploration efforts, resulting in slight growth in sales revenue and volume of the product Su Tai [1] - The revenue from the product Shutaqing decreased due to external environment and industry policy factors; the company is exploring multiple channels for the Shutaqing product market and focusing on expanding the marketing efforts for polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shusitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shuyi Qing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shuchang Qing)" [1] - The company expects non-recurring gains and losses for the year 2025 to be approximately 4.75 million yuan, with specific data to be disclosed in the 2025 annual report [1]

Group 1 - The core point of the article is that Shengxiang Biotechnology (688289.SH) is currently experiencing a decline in stock price, closing at 20.67 yuan with a drop of 6.56%, indicating a state of being below its initial public offering (IPO) price [1] - Shengxiang Biotechnology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 28, 2020, with an issuance of 40 million shares at an IPO price of 50.48 yuan per share [1] - The highest price recorded for Shengxiang Biotechnology since its listing was 155.55 yuan on the first trading day [1] Group 2 - The total amount of funds raised by Shengxiang Biotechnology was 201.92 million yuan, with a net amount of 186.93 million yuan, exceeding the original plan by 131.27 million yuan [1] - The company planned to use the raised funds for projects including the production base for precision intelligent molecular diagnostic systems, upgrading the research and development center, and enhancing the marketing network and information technology [1] - The listing expenses for Shengxiang Biotechnology amounted to 150 million yuan, with underwriting fees to the lead underwriters, Western Securities and CITIC Securities, totaling 128 million yuan [2] Group 3 - On May 26, 2022, Shengxiang Biotechnology announced a profit distribution plan for the year 2021, proposing a cash dividend of 3.75 yuan (including tax) for every 10 shares held, along with a capital reserve conversion of 4.8 shares for every 10 shares [2]

Summary of Key Points Core Viewpoint - Baiotai (688177.SH) has experienced a decline in stock price, closing at 23.82 yuan with a drop of 3.95%, indicating a state of breaking down [1]. Company Overview - Baiotai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 21, 2020, with an initial offering price of 32.76 yuan per share [1]. - The company issued 60 million shares during its IPO, with China International Capital Corporation serving as the sponsor and representatives being Xie Xianming and Zhao Zeyu, while GF Securities and Morgan Stanley Huaxin Securities acted as joint underwriters [1]. IPO Financials - The total funds raised from the IPO amounted to 1.966 billion yuan, with a net amount of 1.876 billion yuan after deducting issuance costs [1]. - The final net fundraising amount was 124 million yuan less than the original plan of 2 billion yuan, which was intended for drug research and development, marketing network construction, and working capital supplementation [1]. - The total issuance costs for the IPO were 89.4002 million yuan, with 77.8302 million yuan paid to the sponsor and joint underwriters for underwriting and sponsorship fees [1]. Stock Performance - On the first day of trading, Baiotai reached an intraday high of 78.00 yuan per share, reflecting strong initial market interest [1].

Core Viewpoint - The company Baotai expects to reduce its net loss for the fiscal year 2025 compared to the previous year, projecting a net profit attributable to the parent company of between -280 million yuan and -390 million yuan, which represents a reduction in loss of between 120.30 million yuan and 230.30 million yuan [1] Group 1 - The reduction in loss is attributed to the company's market expansion efforts [1] - Sales of Adalimumab and Tocilizumab have increased, contributing to the improved financial outlook [1] - The launch of Ustekinumab in the United States has also positively impacted revenue through licensing and sales growth [1]

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant contributions from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes the company's self-developed BFA01 adjuvant [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix, indicating a competitive landscape for Ruike's new product [3]

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Jiangsu Ruike Biotechnology Co., Ltd.'s application for the conversion of 141,953,489 shares from domestic unlisted to overseas listed shares for trading on the Hong Kong Stock Exchange [1][4][5] - The shareholders involved in this conversion include various investment partnerships and funds, with significant holdings from entities such as Taizhou Yuangong Technology Partnership and Springleaf Investments Pte. Ltd. [4][5] Group 2 - Ruike Biotechnology has recently had its new drug application for the recombinant herpes zoster vaccine REC610 accepted by the National Medical Products Administration, which utilizes a novel adjuvant BFA01 developed by the company [3] - Currently, the only other recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix [3]

Core Viewpoint - The stock of Innovent Biologics (01801) rose nearly 3% following the announcement that its drug IBI3003 received Fast Track Designation from the FDA for treating relapsed or refractory multiple myeloma [1] Group 1: Company Developments - Innovent Biologics' IBI3003 is a tri-specific antibody targeting GPRC5D/BCMA/CD3, which is currently undergoing Phase I/II clinical trials in China, Australia, and the United States [1] - The FDA's Fast Track Designation is aimed at patients who have undergone at least four lines of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody [1] Group 2: Market Reaction - As of the report, Innovent Biologics' stock price increased by 2.2%, reaching 83.6 HKD, with a trading volume of 204 million HKD [1]

Core Viewpoint - Cinda Biologics (01801) shares rose nearly 3%, currently up 2.2% at HKD 83.6, with a trading volume of HKD 204 million [1] Group 1: Company Developments - Cinda Biologics announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 received Fast Track Designation from the U.S. FDA on January 27, 2026 [1] - The intended indication for IBI3003 is for relapsed or refractory multiple myeloma (R/R MM) patients who have undergone at least four lines of treatment, including a proteasome inhibitor (Pl), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody [1] - IBI3003 is developed using Cinda Biologics' proprietary Sanbody platform and is currently undergoing Phase I/II clinical trials in China, Australia, and soon in the U.S. to explore its efficacy and safety in R/R MM [1]